185 related articles for article (PubMed ID: 15252268)
1. Mycophenolate mofetil in multiple sclerosis.
Frohman EM; Brannon K; Racke MK; Hawker K
Clin Neuropharmacol; 2004; 27(2):80-3. PubMed ID: 15252268
[TBL] [Abstract][Full Text] [Related]
2. Spotlight on: clinical development of mycophenolate mofetil in multiple sclerosis.
Davies SL; Moral MA
Drug News Perspect; 2006 Dec; 19(10):632-3. PubMed ID: 17299605
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : a retrospective analysis of 106 patients.
Siepmann K; Huber M; Stübiger N; Deuter C; Zierhut M
Graefes Arch Clin Exp Ophthalmol; 2006 Jul; 244(7):788-94. PubMed ID: 16163494
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil for relapsing-remitting multiple sclerosis.
Xiao Y; Huang J; Luo H; Wang J
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD010242. PubMed ID: 24505016
[TBL] [Abstract][Full Text] [Related]
5. [Efficiency of mycophenolate mofetil in the treatment of intermediate and posterior uveitis].
Greiner K; Varikkara M; Santiago C; Forrester JV
Ophthalmologe; 2002 Sep; 99(9):691-4. PubMed ID: 12219257
[TBL] [Abstract][Full Text] [Related]
6. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil improves neurological function and alters blood T-lymphocyte subsets in rats with experimental autoimmune encephalomyelitis.
Zhu Z; You W; Xie Z; Wang P; Liu Z; Wang C; Bi J
J Int Med Res; 2014 Apr; 42(2):530-41. PubMed ID: 24496150
[TBL] [Abstract][Full Text] [Related]
8. [Mycophenolate mofetil in treatment of childhood nephrotic syndrome--preliminary report].
Kwinta-Rybicka J; Wilkosz K; Wierzchowska-Słowiacze EK; Ogarek I; Moczulska A; Stec Z; Pełkowska A; Sancewicz-Pach K; Pietrzyk JA
Przegl Lek; 2006; 63 Suppl 3():44-8. PubMed ID: 16898486
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients.
Takebe N; Cheng X; Wu S; Bauer K; Goloubeva OG; Fenton RG; Heyman M; Rapoport AP; Badros A; Shaughnessy J; Ross D; Meisenberg B; Tricot G
Clin Cancer Res; 2004 Dec; 10(24):8301-8. PubMed ID: 15623606
[TBL] [Abstract][Full Text] [Related]
10. Analysis of T2 intensity by magnetic resonance imaging of deep gray matter nuclei in multiple sclerosis patients: effect of immunomodulatory therapies.
Pawate S; Wang L; Song Y; Sriram S
J Neuroimaging; 2012 Apr; 22(2):137-44. PubMed ID: 21707826
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolic acid exposure and complement fraction C3 influence inosine 5'-monophosphate dehydrogenase activity in systemic lupus erythematosus.
Mino Y; Naito T; Shimoyama K; Ogawa N; Kawakami J
Ann Clin Biochem; 2017 Jul; 54(4):490-494. PubMed ID: 27538768
[TBL] [Abstract][Full Text] [Related]
12. [Mycophenolate mofetil--20 years of experience in treatment of rheumatic diseases].
Walkiewicz-Pielaszek K; Swacha M; Bułło-Piontecka B; Rutkowski B; Olesiñska M
Postepy Hig Med Dosw (Online); 2015 Feb; 69():176-87. PubMed ID: 25661917
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease.
Larkin G; Lightman S
Ophthalmology; 1999 Feb; 106(2):370-4. PubMed ID: 9951492
[TBL] [Abstract][Full Text] [Related]
14. Immunologic therapy for secondary and primary progressive multiple sclerosis.
Myers LW
Curr Neurol Neurosci Rep; 2001 May; 1(3):286-93. PubMed ID: 11898531
[TBL] [Abstract][Full Text] [Related]
15. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients.
Michel L; Vukusic S; De Seze J; Ducray F; Ongagna JC; Lefrère F; Jacq-Foucher M; Confavreux C; Wiertlewski S; Laplaud DA
J Neurol Neurosurg Psychiatry; 2014 Mar; 85(3):279-83. PubMed ID: 23704316
[TBL] [Abstract][Full Text] [Related]
17. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients.
Glander P; Hambach P; Braun KP; Fritsche L; Waiser J; Mai I; Neumayer HH; Budde K
Int J Clin Pharmacol Ther; 2003 Oct; 41(10):470-6. PubMed ID: 14703953
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of therapy with mycophenolate mofetil in chronic non-infectious uveitis.
Doycheva D; Zierhut M; Blumenstock G; Stuebiger N; Deuter C
Graefes Arch Clin Exp Ophthalmol; 2011 Aug; 249(8):1235-43. PubMed ID: 21720813
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group.
Transplantation; 1999 Aug; 68(3):391-6. PubMed ID: 10459543
[TBL] [Abstract][Full Text] [Related]
20. A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation.
Behrend M
Clin Nephrol; 1996 May; 45(5):336-41. PubMed ID: 8738667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
